These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
808 related articles for article (PubMed ID: 24068788)
1. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898 [TBL] [Abstract][Full Text] [Related]
3. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Wiestler B; Capper D; Hovestadt V; Sill M; Jones DT; Hartmann C; Felsberg J; Platten M; Feiden W; Keyvani K; Pfister SM; Wiestler OD; Meyermann R; Reifenberger G; Pietsch T; von Deimling A; Weller M; Wick W Neuro Oncol; 2014 Dec; 16(12):1630-8. PubMed ID: 25028501 [TBL] [Abstract][Full Text] [Related]
4. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110 [TBL] [Abstract][Full Text] [Related]
5. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Weller M; Stupp R; Hegi ME; van den Bent M; Tonn JC; Sanson M; Wick W; Reifenberger G Neuro Oncol; 2012 Sep; 14 Suppl 4(Suppl 4):iv100-8. PubMed ID: 23095825 [TBL] [Abstract][Full Text] [Related]
6. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037 [TBL] [Abstract][Full Text] [Related]
7. Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions. Roszkowski K; Furtak J; Zurawski B; Szylberg T; Lewandowska MA Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834917 [TBL] [Abstract][Full Text] [Related]
8. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Chamberlain MC Neurology; 2014 Jun; 82(23):2147-8. PubMed ID: 24912510 [No Abstract] [Full Text] [Related]
9. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas. Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718 [TBL] [Abstract][Full Text] [Related]
10. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment. Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199 [TBL] [Abstract][Full Text] [Related]
11. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Boots-Sprenger SH; Sijben A; Rijntjes J; Tops BB; Idema AJ; Rivera AL; Bleeker FE; Gijtenbeek AM; Diefes K; Heathcock L; Aldape KD; Jeuken JW; Wesseling P Mod Pathol; 2013 Jul; 26(7):922-9. PubMed ID: 23429602 [TBL] [Abstract][Full Text] [Related]
12. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation. Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197 [TBL] [Abstract][Full Text] [Related]
13. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas. Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441 [TBL] [Abstract][Full Text] [Related]
14. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas. Li MY; Wang YY; Cai JQ; Zhang CB; Wang KY; Cheng W; Liu YW; Zhang W; Jiang T PLoS One; 2015; 10(6):e0130872. PubMed ID: 26115094 [TBL] [Abstract][Full Text] [Related]
15. Molecular markers in low-grade gliomas: predictive or prognostic? Hartmann C; Hentschel B; Tatagiba M; Schramm J; Schnell O; Seidel C; Stein R; Reifenberger G; Pietsch T; von Deimling A; Loeffler M; Weller M; Clin Cancer Res; 2011 Jul; 17(13):4588-99. PubMed ID: 21558404 [TBL] [Abstract][Full Text] [Related]
16. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448 [TBL] [Abstract][Full Text] [Related]
17. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. van den Bent MJ; Dubbink HJ; Marie Y; Brandes AA; Taphoorn MJ; Wesseling P; Frenay M; Tijssen CC; Lacombe D; Idbaih A; van Marion R; Kros JM; Dinjens WN; Gorlia T; Sanson M Clin Cancer Res; 2010 Mar; 16(5):1597-604. PubMed ID: 20160062 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas. Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049 [TBL] [Abstract][Full Text] [Related]
19. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672 [TBL] [Abstract][Full Text] [Related]
20. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response. Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]